The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Sex differences in burden of adverse events in patients receiving immunotherapy.
 
Rosalba Miceli
No Relationships to Disclose
 
Hanna Eriksson
Honoraria - BMS (Inst); Novartis/Pfizer (Inst); Pierre Fabre (Inst)
Consulting or Advisory Role - BMS (Inst); MSD (Inst); Pierre Fabre (Inst)
Research Funding - Skyline Diagnostics (Inst)
 
Alex J. Eustace
No Relationships to Disclose
 
Giuseppe Lo Russo
Consulting or Advisory Role - Amgen (Inst); AstraZeneca/MedImmune; Bristol-Myers Squibb/Medarex; GlaxoSmithKline; italfarmaco; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda (Inst)
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb/Medarex (Inst); Celgene (Inst); GlaxoSmithKline (Inst); MSD Oncology; MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BMS; MSD; Roche
 
Salvatore Alfieri
No Relationships to Disclose
 
Maria Moksnes Bjaanæs
Speakers' Bureau - Bristol-Myers Squibb/Roche
 
Filippo Pietrantonio
Honoraria - Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Lilly; Merck Serono; MSD Oncology; Pierre Fabre; SERVIER
Consulting or Advisory Role - Amgen; Bayer; Merck; Merck Serono; Merck Serono; MSD Oncology; SERVIER
Research Funding - Astrazeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst)
Travel, Accommodations, Expenses - Pierre Fabre; Pierre Fabre
 
Loris De Cecco
Research Funding - Bristol Myers Squibb Foundation (Inst)
 
Arsela Prelaj
Consulting or Advisory Role - Bristol Myers Squibb Foundation
Travel, Accommodations, Expenses - Janssen
Other Relationship - ML Cube; Owkin
 
Claudia Proto
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Janssen; Roche
Speakers' Bureau - Bristol-Myers Squibb; Roche
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo Pharmaceutical (Inst); Janssen (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Roche
 
Johan Franzen
No Relationships to Disclose
 
Deirdre McDonnell
No Relationships to Disclose
 
Jose Javier Berenguer Pina
No Relationships to Disclose
 
Teresa Beninato
No Relationships to Disclose
 
Laura Mazzeo
No Relationships to Disclose
 
Patrizia Giannatempo
Honoraria - Astellas Pharma; Gilead Sciences; Janssen medical Affairs; Pfizer
Consulting or Advisory Role - Astellas Pharma; Gilead Sciences; Janssen Oncology; Merck; Pfizer
Research Funding - AstraZeneca; Ipsen; MSD Oncology
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Roche; Bristol-Myers Squibb/Roche; Pfizer
 
Elena Verzoni
Consulting or Advisory Role - Janssen Oncology; MSD/AstraZeneca; Pfizer
Speakers' Bureau - Ipsen; Janssen Oncology; MSD Oncology; Novartis
 
John Crown
Employment - OncoAssure; OncoMark
Stock and Other Ownership Interests - OncoAssure; OncoMark
Honoraria - AstraZeneca; MSD Oncology; Pfizer; Pierre Fabre
Consulting or Advisory Role - AstraZeneca; MSD Oncology
Speakers' Bureau - Pfizer
Research Funding - BMS GmbH & Co. KG (Inst); MSD Oncology (Inst); Novartis (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - WO2020011770 (A1) - A method of predicting response to treatment in cancer patients
Travel, Accommodations, Expenses - Astrazeneca; Daiichi Sankyo Europe GmbH; MSD; Pfizer; Regeneron; Roche
 
Aslaug Helland
Research Funding - AstraZeneca (Inst); Bristol Myers Squibb (Inst); Illumina (Inst); InCyte (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Roche (Inst); Ultimovacs (Inst)